Eli Lilly Jumps On Expedited Plans For Alzheimer's Drug, Biogen Falls

Eli Lilly announced that the Food and Drug Administration granted Breakthrough Therapy designation for donanemab, its investigational antibody therapy for Alzheimer's disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.